Financial burdens of HIV and chronic disease on people living with HIV in Côte d'Ivoire: A cross-sectional out-of-pocket expenditure study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
03
2020
accepted:
11
07
2021
entrez:
29
7
2021
pubmed:
30
7
2021
medline:
4
11
2021
Statut:
epublish
Résumé
Although people living with HIV in Côte d'Ivoire receive antiretroviral therapy (ART) at no cost, other out-of-pocket (OOP) spending related to health can still create a barrier to care. A convenience sample of 400 adults living with HIV for at least 1 year in Côte d'Ivoire completed a survey on their health spending for HIV and chronic non-communicable diseases (NCDs). In addition to descriptive statistics, we performed simple linear regression analyses with bootstrapped 95% confidence intervals. 365 participants (91%) reported OOP spending for HIV care, with a median of $16/year (IQR 5-48). 34% of participants reported direct costs with a median of $2/year (IQR 1-41). No participants reported user fees for HIV services. 87% of participants reported indirect costs, with a median of $17/year (IQR 7-41). 102 participants (26%) reported at least 1 NCD. Of these, 80 (78%) reported OOP spending for NCD care, with a median of $50/year (IQR 6-107). 76 participants (95%) with both HIV and NCDs reported direct costs, and 48% reported paying user fees for NCD services. Participants had missed a median of 2 HIV appointments in the past year (IQR 2-3). Higher OOP costs were not associated with the number of HIV appointments missed. 21% of participants reported spending over 10% of household income on HIV and/or NCD care. Despite the availability of free ART, most participants reported OOP spending. OOP costs were much higher for participants with co-morbid NCDs.
Sections du résumé
BACKGROUND
Although people living with HIV in Côte d'Ivoire receive antiretroviral therapy (ART) at no cost, other out-of-pocket (OOP) spending related to health can still create a barrier to care.
METHODS
A convenience sample of 400 adults living with HIV for at least 1 year in Côte d'Ivoire completed a survey on their health spending for HIV and chronic non-communicable diseases (NCDs). In addition to descriptive statistics, we performed simple linear regression analyses with bootstrapped 95% confidence intervals.
FINDINGS
365 participants (91%) reported OOP spending for HIV care, with a median of $16/year (IQR 5-48). 34% of participants reported direct costs with a median of $2/year (IQR 1-41). No participants reported user fees for HIV services. 87% of participants reported indirect costs, with a median of $17/year (IQR 7-41). 102 participants (26%) reported at least 1 NCD. Of these, 80 (78%) reported OOP spending for NCD care, with a median of $50/year (IQR 6-107). 76 participants (95%) with both HIV and NCDs reported direct costs, and 48% reported paying user fees for NCD services. Participants had missed a median of 2 HIV appointments in the past year (IQR 2-3). Higher OOP costs were not associated with the number of HIV appointments missed. 21% of participants reported spending over 10% of household income on HIV and/or NCD care.
DISCUSSION AND CONCLUSIONS
Despite the availability of free ART, most participants reported OOP spending. OOP costs were much higher for participants with co-morbid NCDs.
Identifiants
pubmed: 34324545
doi: 10.1371/journal.pone.0255074
pii: PONE-D-20-08083
pmc: PMC8320983
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0255074Subventions
Organisme : HRSA HHS
Pays : United States
Organisme : PEPFAR
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Infect Dis. 2005 Jul 15;41(2):217-24
pubmed: 15983918
Int J STD AIDS. 2005 Jan;16(1):38-41
pubmed: 15705271
PLoS Med. 2019 Jan 8;16(1):e1002716
pubmed: 30620729
J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):e52-60
pubmed: 26371611
BMC Public Health. 2017 Dec 15;17(1):954
pubmed: 29246206
AIDS. 2018 Jul 31;32(12):1563-1569
pubmed: 29762172
AIDS. 2018 Jul 1;32 Suppl 1:S5-S20
pubmed: 29952786
Saudi J Kidney Dis Transpl. 2018 Jan-Feb;29(1):153-159
pubmed: 29456222
PLoS One. 2016 Dec 2;11(12):e0167117
pubmed: 27911921
J Int AIDS Soc. 2019 Jul;22(7):e25364
pubmed: 31353831
Eur Heart J Suppl. 2019 Apr;21(Suppl D):D47-D49
pubmed: 31043876
Ecohealth. 2015 Mar;12(1):98-103
pubmed: 25361853
Lancet. 2018 May 19;391(10134):2047-2058
pubmed: 29627161
AIDS Care. 2007 May;19(5):658-65
pubmed: 17505927
PLoS One. 2015 Jul 08;10(7):e0127199
pubmed: 26154083
PLoS One. 2015 Oct 08;10(10):e0140298
pubmed: 26447777
J Int Assoc Provid AIDS Care. 2018 Jan-Dec;17:2325958218774775
pubmed: 29770721
AIDS. 2018 Mar 27;32(6):773-782
pubmed: 29369158
PLoS One. 2010 Jun 18;5(6):e11213
pubmed: 20585454